Wall Street Zen Upgrades CapsoVision (NASDAQ:CV) to Hold

CapsoVision (NASDAQ:CV) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday.

CV has been the topic of a number of other reports. Zacks Research upgraded CapsoVision to a “hold” rating in a research report on Wednesday, November 5th. Benchmark reissued a “speculative buy” rating on shares of CapsoVision in a research report on Friday, November 14th. Weiss Ratings reissued a “sell (e)” rating on shares of CapsoVision in a research report on Monday, December 29th. Finally, Roth Capital set a $7.00 target price on CapsoVision in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, CapsoVision currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.00.

CapsoVision Stock Down 12.9%

NASDAQ CV opened at $6.10 on Friday. The firm’s fifty day moving average is $8.24. The stock has a market capitalization of $285.72 million and a P/E ratio of -2.79. CapsoVision has a fifty-two week low of $3.43 and a fifty-two week high of $15.37.

CapsoVision (NASDAQ:CV) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The firm had revenue of $3.54 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CapsoVision stock. New York State Common Retirement Fund bought a new position in shares of CapsoVision, Inc. (NASDAQ:CV) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 7,114 shares of the company’s stock, valued at approximately $34,000.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.